Additionally, Tseng-Rogenski et al. (2015) have shown that the presence of this fusion protein in colon cancer cell lines prevents the translocation of MSH3 from the nucleus to the cytoplasm following IL-6 treatment. This evidence concerns the gene MSH3 and malignant colon neoplasm.